Imatinib
Imatinib Phase 3 dose trials (combined analysis on label)
Novartis · Phase 3 · Completed · Enrollment 1640
| Arm | Reported safety |
|---|---|
| Imatinib 400 mg daily | n/r |
| Imatinib 800 mg daily | n/r |
A count stays a count. This page does not turn a count into a percent.